Glynamic M 2mg/500mg Tablet is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. The synergistic action of these two agents addresses multiple pathophysiological defects in type 2 diabetes, making Glynamic M effective in achieving and maintaining target blood glucose levels when diet and exercise alone are insufficient. This combination is particularly beneficial for patients inadequately controlled on monotherapy with either agent. Glynamic M should be used under medical supervision with regular monitoring of blood glucose, renal function, and potential side effects such as hypoglycemia, gastrointestinal disturbances, and lactic acidosis risk associated with Metformin. Dosage adjustments may be necessary based on patient response and tolerability. It is contraindicated in patients with severe renal impairment, metabolic acidosis, or hypersensitivity to its components. Proper adherence to prescribed therapy and lifestyle modifications are essential for optimal therapeutic outcomes with Glynamic M 2mg/500mg Tablet.